Back

Antibodies targeting HSV glycoprotein B require effector functions to protect neonatal mice

Slein, M. D.; Jimenez, L. M.; Backes, I. M.; Turnbaugh, E. M.; Garland, C. R.; MacDonald, S. W.; Balazs, A. B.; Leib, D. A.; Ackerman, M. E.

2025-07-30 immunology
10.1101/2025.07.25.666806 bioRxiv
Show abstract

Glycoprotein B (gB) serves as the viral fusion protein for herpes simplex virus (HSV), mediating fusion between viral and host membranes resulting in infection. As such, gB represents a potentially critical target for the host immune system with high potential relevance for vaccine design. Here we investigated the mechanisms of protection for a panel of gB-specific monoclonal antibodies (mAb) in a mouse model of neonatal HSV (nHSV) infection. Viral neutralization contributed, but Fc effector functions were critical for mAb-mediated protection against nHSV mortality, depending on dose. Moreover, AAV-mediated in vivo expression of a gB-specific mAb in mice provided transgenerational protection against HSV-1 and HSV-2 mortality in their offspring. These findings demonstrate that antibodies targeting gB can serve as potent therapeutics and that they require diverse functional profiles to afford optimal protection, informing vaccine design.

Published in Journal of Virology (predicted rank #1) · training set

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.